Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy

@inproceedings{Phillips2019TolerogenicDC,
  title={Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy},
  author={Brett Eugene Phillips and Yesica Garciafigueroa and Carl L Engman and M. Alejandra Trucco and Nick Giannoukakis},
  booktitle={Front. Immunol.},
  year={2019}
}
Tolerogenic dendritic cells and T-regulatory cells are two immune cell populations with the potential to prevent the onset of clinical stage type 1 diabetes, and manage the beginning of underlying autoimmunity, at the time-at-onset and onwards. Initial phase I trials demonstrated that the administration of a number of these cell populations, generated ex vivo from peripheral blood leukocytes, was safe. Outcomes of some of these trials also suggested some level of autoimmunity regulation, by the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 104 REFERENCES

exploring therapeutic impact on human autoimmune disease

BE Phillips, Y Garciafigueroa, TruccoM, Giannoukakis N. Clinical tolerogenic dendritic cells
  • Front Immunol.
  • 2017
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…